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Abstract: A series of novel N-((2,5-diaryl-3-trifluoroacetyl)-1H-indol-7-yl)acetamides has been prepared
via a successive and one-pot reaction sequence involving initial trifluoroacetic acid-mediated Beckmann
rearrangement of the oximes derived from the 1-(2,5-diaryl-1H-indol-7-yl)ethanones, followed
by trifluoroacetylation of the incipient N-(2,5-diaryl-1H-indol-7-yl)-acetamides with trifluoroacetic
anhydride. The prepared compounds were evaluated for potential in vitro antiplasmodial properties.
Preliminary results from antiplasmodial activity against the chloroquine-sensitive 3D7 strain of
Plasmodium falciparum revealed that a combination of 2-(4-flurophenyl)- and 5-(4-fluorophenyl) or
2-(4-flurophenyl)- and 4-fluorostyryl groups in compounds 3(a,f) and 4(a,g), for example, is required for
biological activity for both series of compounds. Their possible mode of action against the plasmodial
parasite is explained theoretically through molecular docking of the most active compounds against
the parasite lactate dehydrogenase (pLDH). These compounds were docked at the entrance of NAD+
in pLDH presumably hindering entry of lactate to cause the observed inhibition effect of pLDH.
The four compounds were found to exhibit low toxicity against monkey kidney Vero cells at the highest
concentrations tested.
Keywords: N-(2,5-diaryl-1H-indol-7-yl)acetamides; N-(3-trifluoroacetylindol-7-yl)acetamides;
antiplasmodial activity; cytotoxicity; molecular docking
1. Introduction
There has been growing interest in the development of efficient methods that allow for rapid
access to functionalized indoles with different substitution pattern on the heterocyclic and aromatic
rings due to their diverse biological properties, which include antimicrobial, antimalarial, anti-oxidant,
anticancer and antitubercular activities [1–3]. The 7-aminoindole moiety constitutes an important
scaffold for the development of compounds with antimalarial and anti-oxidant activities [3–7] and some
of the compounds serve as anion receptors especially for dihydrogen phosphate [8]. Melatonin (A),
which is shown in Figure 1, is an example of a carboxamide-appended indole derivative which plays a
central role in the control of Plasmodium falciparum replication and establishment of parasitemia [9].
The presence of a hydrogen-bond acceptor at the C-3 position of an indole moiety such as carbonyl
group is important for interaction with the biological receptors [10].
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Figure 1. Structure of melatonin (A). 
In a previous study we evaluated some 1-(2,5-diarylindol-7-yl)ethanones for in vitro cytotoxicity 
against the human breast adenocarcinoma (MCF-7) and human cervical cancer (HeLa) cell lines [11]. 
In an effort to synthesize new compounds with antimalarial potential, we decided to transform the 
1-(2,5-diarylindol-7-yl)ethanones into analogues of melatonin. Our strategy towards the indole-
appended acetamides involved the Beckmann rearrangement of oximes derived from the 1-(2,5-
diarylindol-7-yl)ethanones to afford the N-(indol-7-yl)acetamides. The latter were, in turn, 
transformed via C-3 trifluoroacetylation to afford the corresponding N-(2,5-diaryl-3-trifluoro-
acetylindol-7-yl)acetamides. The prepared N-(indol-7-yl)acetamides and their 3-trifluoroacetyl 
derivatives were evaluated for potential in vitro antiplasmodial properties against the chloroquine-
sensitive 3D7 strain of Plasmodium falciparum to correlate structural variations to biological activity. 
The possible mode of action of these compounds against the plasmodium parasite is explained 
theoretically through molecular docking of the most active compounds against the parasite lactate 
dehydrogenase (pLDH). 
2. Results and Discussion 
2.1. Chemistry 
In order to prepare the N-(2,5-diarylindol-7-yl)acetamides, we required the oxime derivatives of 
compounds 1 for participation in the Beckmann rearrangement. We reacted the known 1-(2,5-
diarylindol-7-yl)ethanones 1a–g [11] with hydroxylamine hydrochloride in the presence of pyridine 
in ethanol under reflux and isolated the corresponding oximes 2a–g by column chromatography on 
silica gel (Scheme 1). The oxime derivatives were characterised using a combination of NMR (1H and 
13C) and IR spectroscopic techniques, complemented with mass spectrometry. Attempted Beckmann 
rearrangement of the keto-oximes 2 using molecular iodine in anhydrous acetonitrile [12] or 
triphenylphosphine-iodine catalyst complex in acetonitrile under reflux [13], led to the recovery of 
the starting material in both cases. We then decided to make use of a strong acid to promote the 
Beckmann rearrangement of compounds 2. In this case we opted for the low boiling and water 
miscible trifluoroacetic acid (TFA) which has been used extensively in organic synthesis to promote 
other types of rearrangement reactions, functional group deprotections, oxidations, reductions, 
condensations, hydroarylations and trifluoromethylations [14]. TFA in aprotic solvents was 
previously found to promote the Beckmann rearrangement of keto-oximes into amides or lactams [15]. 
Based on this literature precedent, we subjected the oxime derivatives 2a–g to TFA in acetonitrile 
under reflux for 2 h (Scheme 1). After aqueous workup and purification by silica gel column 
chromatography, we isolated compounds characterised using a combination of spectroscopic 
techniques as the desired novel N-(2,5-diarylindol-7-yl) acetamides 3a–g. The proton NMR spectra of 
these amide derivatives revealed the presence of a singlet at about δ 9.70 ppm corresponding to NH 
of the amide group. Formation of these compounds through aryl migration, on the other hand, was 
confirmed by a significant up-field shift of the methyl protons to around δ 2.19 ppm compared to 
those in the 1H-NMR spectra of 1 (around δ 2.79 ppm) and 2 (around δ 2.38 ppm). Moreover, their 
carbonyl carbon resonates significantly up-field (δC=O 170 ppm) than that of the corresponding 
precursors 1 (δC=O 200 ppm) and more downfield than substrates 2 (δC=N 155 ppm). The methodology 
described in this investigation for the synthesis of C-7 aminated NH-free indoles is complementary 
to the method developed by Cacchi et al. [16], which makes use of the Buchwald-Hartwig C–N bond 
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Figure 1. Structure of melatonin (A).
In a previous study we evaluated some 1-(2,5-diarylindol-7-yl)ethanones for in vitro
cytotoxicity against the human breast adenocarcinoma (MCF-7) and human cervical cancer
(HeLa) cell lines [11]. In an effort to synthesize new compounds with antimalarial potential,
we decided to transform the 1-(2,5-diarylindol-7-yl)ethanones into analogues of melatonin.
Our strategy towards the indole-appended acetamides involved the Beckmann rearrangement of
oximes derived from the 1-(2,5-diarylindol-7-yl)ethanones to afford the N-(indol-7-yl)acetamides.
The latter were, in turn, transformed via C-3 trifluoroacetylation to afford the corresponding
N-(2,5-diaryl-3-trifluoro-acetylindol-7-yl)acetamides. The prepared N-(indol-7-yl)acetamides and
their 3-trifluoroacetyl derivatives were evaluated for potential in vitro antiplasmodial properties
against the chloroquine-sensitive 3D7 strain of Plasmodium falciparum to correlate structural variations
to biological activity. The possible mode of action of these compounds against the plasmodium parasite
is explained theoretically through molecular docking of the most active compounds against the parasite
lactate dehydrogenase (pLDH).
2. Results and Discussion
2.1. Chemistry
In order to prepare the N-(2,5-diarylindol-7-yl)acetamides, we required the oxime derivatives
of compounds 1 for participation in the Beckmann rearrangement. We reacted the known
1-(2,5-diarylindol-7-yl)ethanones 1a–g [11] with hydroxylamine hydrochloride in the presence
of pyridine in ethanol under reflux and isolated the corresponding oximes 2a–g by column
chromatography on silica gel (Scheme 1). The oxime derivatives were characterised using a
combination of NMR (1H and 13C) and IR spectroscopic techniques, complemented with ass
spectrometry. Attempted Beckmann rearrangement of the keto-oximes 2 using molecular iodine
in anhydrous acetonitrile [12] or triphenylphosphine-iodine catalyst complex in acetonitrile under
reflux [13], led to the recovery of the starting material in both cases. We then decided to make use
of a strong acid to promote the Beckmann rearrangement of compounds 2. In this case we opted
for the low boiling and water miscible trifluoroacetic acid (TFA) which has been used extensively in
organic synthesis to promote other types of rearrangement reactions, functional group deprotections,
oxidations, reductions, condensations, hydroarylations and trifluoromethylations [14]. TFA in aprotic
solvents was previously found to promote the Beckmann rearrangement of keto-oximes into amides
or lactams [15]. Based on this literature precedent, we subjected the oxime derivatives 2a–g to TFA
in acetonitrile under reflux for 2 h (Scheme 1). After aqueous workup and purification by silica gel
column chromatography, we isolated compounds characterised using a combination of spectroscopic
techniques as the desired novel N-(2,5-diarylindol-7-yl) acetamides 3a–g. The proton NMR spectra
of these amide derivatives revealed the presence of a singlet at about δ 9.70 ppm corresponding to
NH of the amide group. Formation of these compounds through aryl migration, on the other hand,
was confirmed by a significant up-field shift of the methyl protons to around δ 2.19 ppm compared
to those in the 1H-NMR spectra of 1 (around δ 2.79 ppm) and 2 (around δ 2.38 ppm). Moreover,
their carbonyl carbon resonates significantly up-field (δC=O 170 ppm) than that of the corresponding
precursors 1 (δC=O 200 ppm) and more downfield than substrates 2 (δC=N 155 ppm). The methodology
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described in this investigation for the synthesis of C-7 aminated NH-free indoles is complementary to
the method developed by Cacchi et al. [16], which makes use of the Buchwald-Hartwig C–N bond
formation of the incipient 7-bromoindoles with primary and secondary amines. Series of 2,5- and
3,5-disubstituted 7-aminoindoles have also been prepared before via a three component Wittig reaction
of pyrrole-3-carboxaldehydes with fumaronitrile and PEt3 followed by chemoselective C-6 alkylation of
the incipient cis-allylic nitriles and subsequent cyclization through an intramolecular Houben−Hoesch
reaction [17].
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of the N-(2,5-diarylindol-7-yl)acetamides 3a–g to evaluate the resultant products for potential 
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them to TFAA (1.5 equiv.) in THF under reflux for 5 h (Scheme 2). Aqueous work-up and column 
chromatography on silica gel afforded the corresponding N-(3-trifluoroacetylindol-7-yl)acetamides 
4a–g in appreciable yields without traces of the N-substituted products. Incorporation of the 
trifluoroacetyl group was confirmed by the absence of a singlet for 3-H in the region δ 6.77–6.92 ppm 
found in the 1H-NMR spectra of the corresponding substrates and the presence of two set of quartets 
at around δ 116.0 ppm and δ 176 ppm in the 13C-NMR spectra of 4, which correspond to the 
trifluoromethyl and carbonyl carbon signals, respectively. The presence of trifluoroacetyl group in 
compounds 4 was further confirmed by an intense peak at around δ −71.0 ppm in their 19F-NMR 
corresponding to -CF3 in analogy with the literature precedents for the analogous 3-
trifluoroacetylindoles [19]. We explored the possibility to effect sequential Beckmann rearrangement 
and C-3 trifluoroacetylation of the oximes 2a–g to afford compounds 4 in a one-pot operation. In this 
case, we subjected the oxime derivatives 2a–g to TFA (1.2 equiv.) in acetonitrile under reflux for 2 h 
followed by addition of TFAA (2 equiv.) and further heating under reflux for additional 5 h. We 
isolated by column chromatography on silica gel compounds 4a–g in high yield. Attempted one-pot 
sequential trifluoroacetylation of 2a–g with TFAA in THF or acetonitrile under reflux followed by 
Beckmann rearrangement, on the other hand, led to incomplete conversion of the incipient 3-
trifluoroacetyl–substituted oximes after 12 h with traces of the 3-trifluoroacetylindoleacetamides 
detected in the crude mixture by thin layer chromatography and 1H-NMR spectroscopy. We were 
also able to obtain single crystals of 4g suitable for X-ray diffraction studies by slow evaporation of a 
DMSO solution [20]. Crystal data and structure refinement, bond lengths and torsion angles are 
enclosed as part of the Supplementary Material. The crystal studied was an inversion twin (Figure 2). 
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Scheme 1. Beckmann rearrangement of the 1-(2,5-diarylindol-7-yl)ethanone oximes 2a–g. Reagents and
conditions: (i) NH2OH·HCl, pyridine, EtOH, reflux, 12 h; (ii) TFA, CH3CN, reflux, 2 h.
Since the presence of a hydrogen-bond acceptor at the C-3 position of an indole moiety such
as carbonyl group is important for interaction with the biological receptors [10], we decided to
incorporate a trifluoroacetyl group at the 3-position of the ambident nucleophilic indole framework of
the N-(2,5-diarylindol-7-yl) cetamides 3a–g t evaluate the resultant products f r potenti l biological
activity. We em loyed the literature conditions [18] on compo n s 3a–g and subjected them to TFAA
(1.5 equiv.) in THF under reflux for 5 h (Sc me 2). Aqueous work-up and colum chromatography on
silica gel afforded the corresponding N-(3-trifluoroacetylindol-7-yl)acetamides 4a–g in appreciable
yields without traces of the N-substituted products. Incorporation of the trifluoroacetyl group was
confirmed by the absence of a singlet for 3-H in the region δ 6.77–6.92 ppm found in the 1H-NMR
spectra of the corresponding substrates and the presence of two set of quartets at around δ 116.0 ppm
and δ 176 ppm in the 13C-NMR spectra of 4, which correspond to the trifluoromethyl and carbonyl
carbon signals, respectively. The presence of trifluoroacetyl group in compounds 4 was further
confirmed by an intens peak at around δ −71.0 ppm in their 19F-NMR corresponding to -CF3 in
analogy ith the literature precedents for the analogous 3- rifluoroacety ind les [19]. We explor d the
possibility to effect sequenti l Beckma n rearrange ent and C-3 trifluoroacetylation of the ximes
2a–g to afford compounds 4 in a one-pot operation. In this case, we subjected the oxime derivatives
2a–g to TFA (1.2 equiv.) in acetonitrile under reflux for 2 h followed by addition of TFAA (2 equiv.)
and further heating under reflux for additional 5 h. We isolated by column chromatography on silica
gel compounds 4a–g in high yield. Attempted one-pot sequential trifluoroacetylation of 2a–g with
TFAA in THF or acetonitrile under reflux followed by Beckmann rearrangement, on the other hand,
led to incomplete conversion of the incipient 3-trifluoroacetyl–substituted oximes after 12 h with traces
of the 3-trifluoroacetylindoleacetamides detected in the crude mixture by thin layer chromatography
and 1H-NMR spectroscopy. We were also able to obtain single crystals of 4g suitable for X-ray
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diffraction studies by slow evaporation of a DMSO solution [20]. Crystal data and structure refinement,
bond lengths and torsion angles are enclosed as part of the Supplementary Material. The crystal studied
was an inversion twin (Figure 2). Thus, X-ray crystallography provided an unambiguous retrospective
proof that the Beckmann rearrangement of the oximes derivatives 2 occurred via aryl migration.
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Figure 2. Oak Ridge Thermal Ellipsoid Plot (ORTEP) diagram of 4g. Displacement ellipsoids are drawn
at the 50% probability level and H atoms are shown as small spheres of arbitrary radii.
As a guide to 7-aminoindoles with potential biological properties, we decided to evaluate
compounds 3a–g and 4a–g for in vitro antiplasmodial activity against the chloroquine-sensitive strain
of malaria parasite P. falciparum (3D7).
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2.2. Biology
2.2.1. Antimalarial Activity Assay
The P. falciparum lactate dehydrogenase enzyme (pLDH) is considered as a potential molecular
target for antimalarial agents due to this parasite’s dependence on glycolysis for energy production.
The in vitro antiplasmodial activity of compounds 3a–g and 4a–g was measured by parasite survival
using parasite lactate dehydrogenase (pLDH) assay with 100% DMSO and chloroquine as the negative
and positive controls, respectively. Lactate dehydrogenase is an enzyme found in all cells that catalyzes
the formation of pyruvate from lactate reducing the co-enzyme nicotinamide adenine dinucleotide
(NAD) to NADH. In parasites, the NAD analogue 3-acetylpyridine adenine nucleotide (APAD) is
reduced to APADH. In contrast, human red blood cell LDH carries out this reaction at a slow rate in
the presence of APAD. The development of APADH is measured, and there is a correlation between
levels of parasitemia and the activity of parasite LDH [21]. The IC50 values are expressed as the %
parasite survival relative to the control, calculated from fitted sigmoidal dose-response curves and are
represented in Table 1 (refer to the supporting information for detailed data).
Table 1. IC50 values of 3a–g and 4a–g and chloroquine against 3D7 strain of P. falciparum.
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4f 4-FC6H4- 4-FC6H4CH=CH- 5.15 ± 1.63 0.47
4g 4-MeOC6H4- 4-FC6H4CH=CH- 3.39 ± 0.86 0.31
Chloroquine 0.01 ± 2.59
a Not determined.
The selectivity index (SI) was calculated as the ratio of IC50 values to the minimal inhibitory
concentration (MIC) values and the compound is considered selective if the selectivity index is
>10 [22]. The concentration of DMSO from 100 µM–5.13 × 10−3 µM had no effect on the parasites
(91–109% parasite survival). The antiplasmodial activity of these novel compounds is between 1400
and 14,000 nM, which is very low compared to chloroquine activity (10 nM) and they have low
selectivity index which ranges between 0.13–0.66. The MICs for compounds 3a, 3b, 3f, 4a–c and 4e–g
was 11 µM while those for 3c, 3e, 3g and 4d was found to be 33 µM and 3d was found to have MIC of
>100 µM. Nevertheless, some of the test compounds 3a–g and 4a–g were found to exhibit moderate
to significant antiplasmodial activity against the chloroquine-sensitive strain of P. falciparum (3D7).
Within series of the 3-unsubstituted N-(indol-7-yl)acetamides 3a–g, for example, the 2-(4-fluoro-phenyl)
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derivatives 3a and 3f substituted with 4-fluorophenyl or 4-fluorostyryl group at the 5-position showed
moderate in vitro antiplasmodial activity against this chloroquine-sensitive strain of P. falciparum with
IC50 values of 1.43 µM (SI = 0.13) and 2.14 µM (SI = 0.20), respectively. Compound 4a substituted
with a trifluoroacetyl group at the 3-position was found to exhibit moderate antiplasmodial activity
(IC50 = 2.52 µM, SI = 0.23) compared to the corresponding C-3 unsubstituted precursor 3a (IC50 =
1.43 µM). The presence of a 3-trifluoroacetyl group in 4f, on the other hand, resulted in moderate
activity (IC50 = 5.15 µM, SI = 0.47) compared to the corresponding C-3 unsubstituted precursor 3f
(IC50 = 2.14 µM). A combination of 2-(4-methoxyphenyl)-, 7-(4-fluorostyryl)- and 3-trifluoroacetyl
groups in 4g resulted in appreciable antiplasmodial activity (IC50 = 3.39 µM, SI = 0.31) compared to
corresponding substrate 3g, which showed no activity against the parasite (IC50 = 14.03 µM) with the
selectivity index of 0.42. The observed increased activity of the 3-trifluoroacetyl derivatives 4 may be
due to the electron-withdrawing effect of the trifluoromethyl group (-CF3) on an indole framework,
which has been found to generally increase the lipophilicity, metabolic stability and activity profile
compared to that of the 3-unsubstituted or 3-acetyl analogues [1]. These preliminary antiplasmodial
activity results also revealed the 4-fluorophenyl or 4-fluorostyryl group as the optimal aryl substituent
at the 5-position of the indole framework of compounds 3 and 4. It has been demonstrated that a
fluorine atom on the aromatic ring generally increase biological activity of the molecule due to its
enhanced lipophilicity [23] and its strong polar interaction with the protein cavity [24]. We took into
account that some of the most active antimalarial drugs are nephrotoxic [25] and then screened the
four most active compounds 3a, 3f, 4a and 4g for toxicity against monkey kidney Vero cells.
2.2.2. Evaluation of Cytotoxicity against Vero Cells
The four compounds 3a, 3f, 4a and 4g were evaluated for their in vitro cytotoxic effects against
monkey kidney Vero cells using the well-established 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl
tetrazolium bromide-based colorimetric cell viability (MTT) assay. The LC50 values (lethal
concentration at which 50% of the cells are killed) of the four compounds (average from three
independent experiments) are listed in Table 2. The LC50 values of the four compounds ranged
from more than 100 µM to 13.78 µM. Overall, all four compounds had low toxicity at the highest
concentrations tested.
Table 2. Cytotoxic effects of 3a, 3f, 4a and 4g against Monkey kidney Vero cell line.
Compound LC50 (µM)
3a 13.78 ± 1.29 0.07
3f >100
4a 32.69 ± 3.63
4g >100
Doxorubicin hydrochloride 1.53 ± 0.22
The development of a new class of drugs that acts through different mechanism of action is of
great importance to circumvent the increasing resistance of P. falciparum to existing antimalarial agents.
To help us understand the observed antiplasmodial activity of compounds 3 and 4 and guide further
structure activity relationship (SAR) studies we conducted molecular docking of 3a, 3f, 4a and 4g
against lactate dehydrogenase (pLDH).
2.3. Molecular Docking Studies of Compounds 3(a,f) and 4(a,g)
4-Hydroxy-1,2,5-oxazole-3-carboxylic acid (OXQ) is the inhibitor for pLDH and co-crystalized
with pLDH [26]. The control docking of OXQ has root mean square deviation (RMSD) of 0.4 Å
(Table 3) with the crystal structure showing the appropriateness of the parameters used in this docking
simulation. Table 3 also shows that the calculated binding free energy for OXQ and lactate (the
substrate pLDH) was −7.11 and −5.58 kcal/mol, respectively. This could be due to the fact that
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OXQ formed 9 hydrogen bonds, but lactate has only 7 hydrogen bond interaction with pLDH/NAD+
(Table 3). In addition, lactate was docked at the same binding site with OXQ, which was near to
the nicotinamide region of NAD+ (Figure 3). This has further demonstrated that OXQ is able to
compete with lactate for the binding site and thus inhibit pLDH. However, compounds 3(a,f) and
4(a,g) were docked near to the adenine region of NAD+ (Figure 3). The binding free energy of 3f
and 4(a,g) were comparable (~−6.4 kcal/mol) while 3a has the weakest binding free energy (−5.95
kcal/mol) (Table 3). Two hydrogen bonds were detected in 3(a,f) while 4(a,g) have only one hydrogen
bond. NAD+ is the co-factor of pLDH and the nicotinamide region was buried deep into the core
of pLDH with relatively narrow channel. Crystal structure of the complex between chloroquine
and P. falciparum lactate dehydrogenase has previously shown this drug within the NADH binding
pocket of the enzyme occupying a position similar to that of the adenyl ring of the cofactor [27].
Molecular docking of chloroquine and quinoline-based derivatives into the glycolytic enzyme lactate
dehydrogenase, on the other hand, showed that these compounds only bind to this site in the absence
of the bound NADH during docking and prefer adenine region of NAD+ which is near to the pLDH
surface [28]. Compounds 3(a,f) and 4(a,g) were also unable to access the narrow channel of the NAD+
binding site and resulted to be docked at the adenine region of NAD+ which is near to the pLDH
surface. Compound 3a is the only test compound to form hydrogen bonding with NAD+ but other
test compounds interacted and formed hydrogen bonding with pLDH. It is also noted that both
fluorophenyl ring ends of 3a, 3f and 4g were in parallel with the phosphate region to adenine region of
NAD+. Therefore, ring stacking interactions of fluorophenyl ring in 3(a,f) and 4g with adenine region
of NAD+ was noticed. However, only the acetyl region of compound 4a was positioned towards the
adenine region of NAD+ with other region pointed away from NAD+.
Table 3. Estimated binding free energy and hydrogen bond of ligands with parasite lactase
dehydrogenase (pLDH) calculated from docking simulation.
Ligand Hb Distance (Å) Interacting Atom FEB (kcal/mol) RMSD (Å)
OXQ (docked)
1.8 ASN140 2HD2–OXQ O7
−7.11 0.4
1.8 ARG109 HE–OXQ O7
1.8 ARG171 2HH1–OXQ O9
1.9 ARG109 2HH2–OXQ O8
2.0 HIS195 HE2–OXQ O7
2.2 ARG171 2HH2–OXQ O8
2.3 NAD O2D–OXQ H5
2.5 HIS195 HE2–OXQ O8
2.7 ARG171 2HH2–OXQ O9
Lactate (LAC)
1.8 ARG171 2HH1–LAC O2
−5.28 -
1.8 ARG171 2HH2–LAC O1
1.8 HIS195 HE2–LAC O3
1.9 ARG109 HE–LAC O3
2.0 ARG109 2HH2–LAC O1
2.5 ASN140 2HD2–LAC O3
2.7 HIS195 HE2–LAC O1
3a
2.1 NAD O1A–3a HN1 −5.95 -2.3 NAD O1A–3a HN2
3f
2.2 LYS102 HN–3f O1 −6.46 -2.7 THR101 HN–3f O1
4a 2.0 GLY99 O–4a HN2 −6.49 -
4g 2.2 LYS102 HZ3–4g O2 −6.40 -
FEB: Free energy of binding.
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3.1. eneral Infor ation
elting points ere recorded on a Thermocouple digital melting point apparatus (Stuart,
Staffordshire, ) and are uncorrected. IR spectra ere recorded as po ders using a Bruker ERTEX
70 FT-IR Spectro eter (Bruker Optics, Billerica, , S ) ith a dia ond TR (attenuated total
reflectance) accessory by using the thin-film method. For column chromatography, Merck kieselgel 60
(0.063–0.200 mm) (Merck KGaA, Frankfurt, Germany) was used as stationary phase. NMR spectra
were obtained as DMSO-d6 solutions using Varian 300 MHz NMR spectrometer (Varian Inc., Palo Alto,
CA, US ) and the chemical shifts are quoted relative to the TMS peak. Low- and high-resolution mass
spectra were recorded using Waters Synapt G2 Quadrupole Time-of-flight mass spectrometer (Waters
Corp., Milford, A, USA) at the University of Stellenbosch Mass Spectrometry Unit. The synthesis
and characterization of compounds 1a–g have been described before [11].
3.2. Typical Procedure for the Synthesis of Oxime Derivatives 2a–g
A stirred mixture of 1 (1 equivalent) and hydroxylamine hydrochloride (1.5 equivalent) and
pyridine (1.5 equivalent) in ethanol (10 mL/mmol of 1) was heated at 80 ◦C overnight. The mixture
was cooled to room temperature and quenched with an ice-cold water and the product was extracted
into chloroform. The combined organic phases were washed with water and dried over anhyd. MgSO4.
The salt was filtered off and the solvent was evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel (20% EtOAc–hexane as eluent) to afford the oxime
derivative 2. The following compounds were prepared in this fashion:
1-(2,5-bis(4-Fluorophenyl)-1H-indol-7-yl) Ethanone Oxime (2a). A mixture of 1a (0.15 g, 0.43 mmol),
hydroxylamine hydrochloride (0.05 g, 0.65 mmol) and pyridine (0.05 g, 0.65 mmol) in ethanol (10 mL)
afforded 2a as a solid (0.15 g, 94%), Rf 0.67, mp. 238–241 ◦C; νmax (ATR) 462, 509, 539, 612, 663, 753,
785, 813, 826, 867, 921, 990, 1099, 1159, 1221, 1232, 1262, 1290, 1373, 1433, 1469, 1514, 3215, 3422 cm−1;
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1H-NMR (DMSO-d6) 2.38 (3H, s, CH3), 6.99 (1H, s, 3-H), 7.26 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.33 (2H, t, J =
9.0 Hz, 3′,5′-H), 7.58 (1H, d, J = 1.2 Hz, 4-H), 7.74 (2H, dd, J = 5.7 and 8.7 Hz, 2”,6”-H), 7.81–7.87 (3H, m,
6-H and 2′,6′-H), 10.85 (1H, s, NH), 11.43 (1H, s, OH); 13C-NMR (DMSO-d6) 11.3, 100.1, 116.0 (d, 2JCF =
21.8 Hz), 116.5 (d, 2JCF = 21.8 Hz), 119.8, 120.3, 120.6, 127.4 (d, 3JCF = 8.0 Hz), 128.6 (d, 4JCF = 3.5 Hz),
129.2 (d, 3JCF = 8.0 Hz), 130.2, 131.8, 133.4, 137.7, 138.3 (d, 4JCF = 3.5 Hz), 155.0, 161.9 (d, 1JCF = 241.7
Hz), 162.3 (d, 1JCF = 243.9 Hz); HRMS (ES): MH+, found 363.1309. C22H17N2F2O+ requires: 363.1309.
1-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-1H-indol-7-yl) Ethanone Oxime (2b). A mixture of 1b (0.15 g,
0.42 mmol), hydroxylamine hydrochloride (0.04 g, 0.62 mmol) and pyridine (0.05 g, 0.62 mmol) in
ethanol (10 mL) afforded 2b as a solid (0.14 g, 87%), Rf 0.47, mp. 212–214 ◦C; νmax (ATR) 433, 518,
541, 554, 615, 664, 692, 752, 784, 827, 921, 986, 1021, 1158, 1182, 1217, 1240, 1315, 1371, 1436, 1464, 1513,
3226, 3405 cm−1; 1H-NMR (DMSO-d6) 2.39 (3H, s, CH3), 3.80 (3H, s, CH3), 6.88 (1H, s, 3-H), 7.05 (2H,
d, J = 8.7 Hz, 3′,5′-H), 7.27 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.57 (1H, d, J = 1.2 Hz, 4-H), 7.72–7.89 (5H, m,
6-H, 2′,6′-H and 2”,6”-H), 10.76 (1H, s, NH), 11.43 (1H, s, OH); 13C-NMR (DMSO-d6) 11.3, 55.7, 98.8,
115.0, 116.0 (d, 2JCF = 20.6 Hz), 119.5, 119.9, 120.2, 124.6, 126.7, 129.1 (d, 3JCF = 8.0 Hz), 130.4, 131.6,
133.1, 138.4 (d, 4JCF = 3.4 Hz), 138.7, 155.1, 159.6, 161.8 (d, 1JCF = 241.7 Hz); HRMS (ES): MH+, found:
375.1507. C23H20N2FO2+ requires: 375.1509.
1-(2-(4-Fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl)ethanone Oxime (2c). A mixture of 1c (0.15 g,
0.43 mmol), hydroxylamine hydrochloride (0.04 g, 0.62 mmol) and pyridine (0.05 g, 0.62 mmol) in
ethanol (10 mL) afforded 2c as a solid (0.14 g, 88%), Rf 0.58, mp. 219–222 ◦C; νmax (ATR) 512, 561, 613,
664, 692, 753, 789, 826, 921, 989, 1023, 1099, 1156, 1182, 1240, 1272, 1371, 1427, 1466, 1520, 3369, 3406
cm−1; 1H-NMR (DMSO-d6) 2.37 (3H, s, CH3), 3.77 (3H, s, OCH3), 6.96 (1H, s, 3-H), 7.00 (2H, d, J =
8.7 Hz, 3”,5”-H), 7.33 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.56 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, d, J = 8.1 Hz,
2”,6”-H), 7.76 (1H, d, J = 1.2 Hz, 6-H), 7.84 (2H, d, J = 8.7 Hz, 2′,6′-H), 10.81 (1H, s, NH), 11.41 (1H, s,
OH); 13C-NMR (DMSO-d6) 11.3, 55.6, 100.1, 114.7, 116.5 (d, 2JCF = 21.8 Hz), 119.2, 120.1, 120.5, 127.3 (d,
3JCF = 9.2 Hz), 128.3, 128.7 (d, 4JCF = 3.5 Hz), 130.2, 132.5, 133.1, 134.2, 137.5, 155.0, 158.7, 162.2 (d, 1JCF
= 242.8 Hz); HRMS (ES): MH+, found: 375.1509. C23H20N2FO2+ requires: 375.1509.
1-(2,5-Bis(4-methoxyphenyl)-1H-indol-7-yl)ethanone Oxime (2d). A mixture of 1d (0.15 g, 0.40 mmol),
hydroxylamine hydrochloride (0.04 g, 0.61 mmol) and pyridine (0.05 g, 0.61 mmol) in ethanol (10 mL)
afforded 2d as a solid (0.14 g, 88%), Rf 0.38, mp. 209–212 ◦C; νmax (ATR) 545, 615, 663, 752, 784, 818,
828, 838, 921, 986, 1028, 1114, 1176, 1236, 1370, 1434, 1466, 1516, 3390, 3416 cm−1; 1H-NMR (DMSO-d6)
2.37 (3H, s, CH3), 3.78 (3H, s, OCH3), 3.80 (3H, s, OCH3), 6.87 (1H, d, s, 3-H), 7.00 (2H, d, J = 8.7
Hz, 3”,5”-H), 7.05 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.53 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, d, J = 8.7 Hz,
2”,6”-H), 7.72 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.74 (1H, d, J = 1.2 Hz, 6-H), 10.71 (1H, s, NH), 11.40 (1H,
s, OH); 13C-NMR (DMSO-d6) 11.2, 55.6, 55.7, 98.7, 114.7, 115.0, 119.0, 119.8, 120.0, 124.7, 126.6, 128.3,
130.4, 132.4, 134.4, 138.5, 155.1, 158.7, 159.5; HRMS (ES): MH+, found: 387.1714. C24H23N2O3+ requires:
387.1709.
1-(5-(4-Fluorophenyl)-2-phenyl)-1H-indol-7-yl)ethanone Oxime (2e). A mixture of 1e (0.15 g, 0.42 mmol),
hydroxylamine hydrochloride (0.04 g, 0.63 mmol) and pyridine (0.05 g, 0.63 mmol) in ethanol (10 mL)
afforded 2e as a solid (0.12 g, 76%), Rf 0.58, mp. 197–199 ◦C; νmax (ATR) 484, 508, 533, 605, 684, 735,
785, 841, 885, 952, 989, 1027, 1137, 1153, 1228, 1274, 1360, 1376, 1449, 1507, 3218, 3412 cm−1; 1H-NMR
(DMSO-d6) 2.39 (3H, s, CH3), 6.98 (1H, d, s, 3-H), 7.19 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.27–7.37 (3H, m, 2x
CH=C and 4′-H), 7.48 (2H, t, J = 7.5 Hz, 3′,5′-H), 7.63 (2H, d, J = 8.7 Hz, 2”,6”-H), 7.69 (1H, d, J = 1.2
Hz, 4-H), 7.78–7.80 (3H, m, 6-H and 2′,6′-H), 10.89 (1H, s, NH), 11.46 (1H, s, OH); 13C-NMR (DMSO-d6)
11.2, 100.0, 116.0 (d, 2JCF = 21.8 Hz), 120.0, 120.1, 120.2, 125.2 (2 × C), 128.3, 128.4 (d, 3JCF = 8.0 Hz),
129.4, 129.5, 129.9, 130.0, 131.9, 133.7, 134.7 (d, 4JCF = 2.3 Hz), 138.4, 155.0, 161.8 (d, 1JCF = 242.8 Hz);
HRMS (ES): MH+, found: 371.1568. C23H20N2FO2+ requires: 371.1560.
1-(2-(4-Fluorophenyl)-5-(4-fluorostyryl)-1H-indol-7-yl)ethanone Oxime (2f). A mixture of 1f (0.15 g,
0.40 mmol), hydroxylamine hydrochloride (0.04 g, 0.60 mmol) and pyridine (0.05g, 0.60 mmol) in
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ethanol (10 mL) afforded 2f as a solid (0.12 g, 75%), Rf 0.67, mp. 238-240 ◦C; νmax (ATR) 480, 509, 540,
578, 667, 718, 745, 772, 784, 805, 832, 881, 949, 988, 1097, 1154, 1223, 1286, 1376, 1431, 1467, 1505, 3234,
3409 cm−1; 1H-NMR (DMSO-d6) 2.37 (3H, s, CH3), 6.95 (1H, d, s, 3-H), 7.19 (2H, t, J = 8.7 Hz, 3”,5”-H),
7.29 (2H, d, J = 17.0 Hz, CH=CH), 7.31 (2H, d, J = 16.2 Hz, CH=CH), 7.32 (2H, t, J = 8.7 Hz, 3′,5′-H),
7.63 (2H, d, J = 8.7 Hz, 2”,6”-H), 7.67 (1H, d, J = 1.2 Hz, 4-H), 7.77 (1H, d, J = 1.2 Hz, 6-H), 7.83 (2H, d,
J = 8.7 Hz, 2′,6′-H), 10.85 (1H, s, NH), 11.42 (1H, s, OH); 13C-NMR (DMSO-d6) 11.3, 100.0, 116.0 (d, 2JCF
21.8 Hz), 116.5 (d, 2JCF = 21.8 Hz), 120.1 (2 × C), 120.2, 125.2, 127.3 (d, 3JCF = 8.0 Hz), 128.3 (d, 3JCF =
8.0 Hz), 128.6 (d, 4JCF = 3.4 Hz), 129.5, 129.9, 130.0, 133.7, 134.7 (d, 4JCF = 3.5 Hz), 137.6, 154.9, 161.8
(d, 1JCF = 242.8 Hz), 162.2 (d, 1JCF = 243.9 Hz); HRMS (ES): MH+, found: 389.1465. C24H19N2F2O+
requires: 389.1465.
1-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone Oxime (2g). A mixture of 1f (0.15 g,
0.39 mmol), hydroxylamine hydrochloride (0.04 g, 0.59 mmol) and pyridine (0.05 g, 0.59 mmol) in
ethanol (10 mL) afforded 2f as a solid (0.11 g, 76%), Rf 0.47, mp. 220–222 ◦C; νmax (ATR) 462, 507, 584,
606, 666, 715, 745, 786, 830, 838, 881, 960, 989, 1020, 1179, 1224, 1249, 1355, 1435, 1467, 1499, 3423, 3461
cm−1; 1H-NMR (DMSO-d6) 2.37 (3H, s, CH3), 3.80 (3H, s, OCH3), 6.85 (1H, s, 3-H), 7.04 (2H, d, J = 8.7
Hz, 3′,5′-H), 7.19 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.23 (2H, d, J = 16.5 Hz, CH=CH), 7.32 (2H, d, J = 16.5 Hz,
CH=CH), 7.61-7.66 (3H, m, 4-H and 2”,6”-H), 7.71 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.75 (1H, d, J = 1.2 Hz,
6-H), 10.75 (1H, s, NH), 11.41 (1H, s, OH); 13C-NMR (DMSO-d6) 11.3, 55.7, 98.7, 115.0 (2 × C), 116.0 (d,
2JCF = 21.8 Hz), 119.8, 119.9, 124.6, 125.0, 126.6, 128.3 (d, 3JCF = 8.0 Hz), 129.3, 130.0, 130.2, 133.5, 134.7
(d, 4JCF = 3.4 Hz), 138.6, 155.0, 159.6, 161.8 (d, 1JCF = 241.6 Hz); HRMS (ES): MH+, found: 401.1664.
C25H22N2FO2+ requires: 401.1665.
3.3. Typical Procedure for the Beckmann Rearrangement of 3a–g
A stirred mixture of 2 (1 equivalent) and TFA (1 equivalent) in acetonitrile (20 mL/mmol of 2)
was heated at 80 ◦C for 2 h. The mixture was cooled to room temperature and quenched with ice-cold
water. The product was extracted with chloroform (3 × 20 mL) and the combined organic layers were
dried over anhydrous MgSO4 and the salt was filtered off. The solvent was evaporated under reduced
pressure and the residue was purified by column chromatography on a silica gel (60% EtOAc–hexane
as eluent) to afford 3 as a solid. Products 3a–f were prepared in this fashion:
N-(2,5-Bis(4-fluorophenyl)-1H-indol-7-yl) Acetamide (3a). A mixture of 2a (0.10 g, 0.28 mmol) and TFA
(0.03 g, 0.28 mmol) in acetonitrile (5 mL) afforded 3a as solid (0.08 g, 80%); Rf 0.51, mp. 272–275 ◦C;
νmax (ATR) 459, 509, 538, 595, 653, 753, 795, 810, 828, 1010, 1102, 1159, 1218, 1230, 1280, 1433, 1474,
1513, 1549, 1630, 1653, 3243, 3339 cm−1; 1H-NMR (DMSO-d6) 2.19 (3H, s, CH3), 6.92 (1H, s, 3-H), 7.25
(2H, t, J = 8.7 Hz, 3′,5′-H), 7.34 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.53 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, d,
J = 8.7 Hz, 2”,6”-H), 7.85–7.90 (3H, m, 6-H and 2′,6′-H), 9.73 (1H, s, NH), 11.10 (1H, s, NH); 13C-NMR
(DMSO-d6) 24.5, 100.3, 113.3, 114.6, 116.0 (d, 2JCF = 21.8 Hz), 116.1, 116.4 (d, 2JCF = 20.6 Hz), 124.4,
127.6 (d, 3JCF = 8.0 Hz), 128.8 (d, 4JCF = 3.4 Hz), 128.9 (d, 3JCF = 8.0 Hz), 130.9, 131.8, 137.6, 138.5 (d,
4JCF = 2.3 Hz), 161.8 (d, 1JCF = 241.6 Hz), 162.2 (d, 1JCF = 242.8 Hz), 169.0; HRMS (ES): MH+, found:
363.1311. C22H17N2F2O+ requires: 363.1231.
N-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3b). A mixture of 2b (0.10 g,
0.27 mmol) and TFA (0.03 g, 0.27 mmol) in acetonitrile (5 mL) afforded 3b as a solid (0.08 g, 75%); Rf
0.37, mp. 213–215 ◦C; νmax (ATR) 518, 533, 595, 745, 774, 811, 831, 1025, 1101, 1177, 1226, 1253, 1367,
1390, 1426, 1472, 1516, 1553, 1609, 1654, 3316 cm−1; 1H-NMR (DMSO-d6) 2.20 (3H, s, CH3), 3.80 (3H, s,
OCH3), 6.80 (1H, s, 3-H), 7.06 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.25 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.49 (1H, d, J =
1.2 Hz, 4-H), 7.62 (2H, t, = 8.7 Hz, 2”,6”-H), 7.76 (2H, d, J = 8.7 Hz 2′,6′-H), 7.87 (1H, d, J = 1.2 Hz, 6-H),
9.72 (1H, s, NH), 11.01 (1H, s, NH); 13C-NMR (DMSO-d6) 24.5, 55.7, 99.0, 112.7, 114.2, 114.9, 116.0 (d,
2JCF 20.6 Hz), 124.3, 124.9, 126.9, 128.4, 128.8 (d, 3JCF 8.0 Hz), 131.1, 131.6, 138.6 (d, 4JCF 3.5 Hz), 159.5,
161.7 (d, 1JCF 241.7 Hz), 169.0; HRMS (ES): MH+, found: 375.1510. C23H20N2FO2+ requires: 375.1509.
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N-(2-(4-Fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3c). A mixture of 2c (0.10 g,
0.27 mmol) and TFA (0.03 g, 0.27 mmol) in acetonitrile (5 mL) afforded 3c as a solid (0.07 g, 73%); Rf
0.47, mp. 216–218 ◦C; νmax (ATR) 505, 523, 550, 600, 719, 749, 786, 805, 826, 1032, 1159, 1178, 1231, 1371,
1427, 1480, 1516, 1566, 1631, 1654, 3258, 3320 cm−1; 1H-NMR (DMSO-d6) 2.19 (3H, s, CH3), 3.77 (3H, s,
OCH3), 6.90 (1H, s, 3-H), 6.99 (2H, d, J = 8.4 Hz, 3”,5”-H), 7.34 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.48 (1H, d,
J = 1.2 Hz, 4-H), 7.53 (2H, t, J = 8.4 Hz, 2”,6”-H), 7.84–7.89 (3H, m, 6-H and 2′,6′-H), 9.71 (1H, s, NH),
11.04 (1H, s, NH); 13C-NMR (DMSO-d6) 24.5, 55.6, 100.2, 113.2, 114.0, 114.7, 116.4 (d, 2JCF = 20.6 Hz),
124.3, 127.5 (d, 3JCF = 8.0 Hz), 128.1, 128.5, 129.1 (d, 4JCF = 3.5 Hz), 130.9, 132.6, 134.5, 137.4, 158.6, 162.1
(d, 1JCF = 242.8 Hz), 169.0; HRMS (ES): MH+, found: 375.1508. C23H20N2FO2+ requires: 375.1509.
N-(2,5-Bis(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3d). A mixture of 2d (0.10 g, 0.26 mmol) and TFA
(0.03 g, 0.26 mmol) in acetonitrile (5 mL) afforded 3d as a solid (0.07 g, 70%); Rf 0.31, mp. 236–239 ◦C;
νmax (ATR) 529, 564, 600, 723, 775, 830, 1030, 1112, 1176, 1244, 1280, 1372, 1432, 1440, 1514, 1550, 1605,
1632, 1656, 3269, 3321 cm−1; 1H-NMR (DMSO-d6) 2.19 (3H, s, CH3), 3.77 (3H, s, OCH3), 3.80 (3H, s,
OCH3), 6.79 (1H, s, 3-H), 6.99 (2H, d, J = 9.0 Hz, 3”,5”-H), 7.06 (2H, d, J = 8.1 Hz, 3′,5′-H), 7.45 (1H, d,
J = 1.2 Hz, 4-H), 7.53 (2H, d, J = 8.4 Hz, 2”,6”-H), 7.76 (2H, d, J = 8.7 Hz 2′,6′-H), 7.83 (1H, d, J = 1.2 Hz,
6-H), 9.70 (1H, s, NH), 10.96 (1H, s, NH); 13C-NMR (DMSO-d6) 24.5, 55.6, 55.7, 98.9, 112.6, 113.7, 114.7,
114.9 (2 × C), 124.2, 125.0, 126.9, 128.0, 131.1, 132.4, 134.6, 138.4, 158.6, 159.4, 168.9; HRMS (ES): MH+,
found: 387.1708. C24H23N2O3+ requires: 387.1709.
(E)-N-(5-(4-Fluorostyryl)-2-phenyl-1H-indol-7-yl) Acetamide (3e). A mixture of 2e (0.10 g, 0.27 mmol) and
TFA (0.03 g, 0.27 mmol) in acetonitrile (5 mL) afforded 3e as a solid (0.08 g, 78%); Rf 0.51, mp. 262–264
◦C; νmax (ATR) 481, 512, 564, 598, 689, 738, 756, 799, 814, 847, 957, 1158, 1204, 1223, 1286, 1353, 1455,
1507, 1646, 3267, 3299 cm−1; 1H-NMR (DMSO-d6) 2.18 (3H, s, CH3), 6.90 (1H, s, 3-H), 7.03 (1H, d, J =
16.5 Hz, CH=CH), 7.16 (2H, t, J = 8.4 Hz, 3”,5”-H), 7.22 (1H, d, J = 16.5 Hz, CH=CH), 7.33–7.35 (1H, m,
4′-H), 7.45–7.48 (3H, m, 4-H and 2”,6”-H), 7.46–7.59 (2H, m, 3′,5′-H), 7.82 (2H, d, J = 7.8 Hz, 2′,6′-H)
7.88 (1H, d, J = 1.2 Hz, 6-H), 9.70 (1H, s, NH), 11.12 (1H, s, NH); 13C-NMR (DMSO-d6) 24.5, 100.2, 112.4,
115.7, 115.9 (d, 2JCF = 20.6 Hz), 124.3, 124.7, 125.5, 128.3, 128.2 (d, 3JCF = 8.0 Hz), 128.4, 129.3, 129.4,
129.5, 130.4, 130.5, 132.3, 134.6 (d, 4JCF = 2.3 Hz), 138.4, 161.7 (d, 1JCF = 242.8 Hz), 170.0; HRMS (ES):
MH+, found: 371.1554. C24H20N2FO+ requires: 371.1560.
(E)-N-(2-(4-Fluorophenyl)-5-(4-fluorostyryl)-1H-indol-7-yl) Acetamide (3f). A mixture of 2f (0.10 g,
0.28 mmol) and TFA (0.03 g, 0.28 mmol) in acetonitrile (5 mL) afforded 3f as a solid (0.08 g, 77%), Rf
0.51, mp. 278–280 ◦C; νmax (ATR) 467, 509, 552, 581, 609, 761, 789, 831, 848, 957, 1012, 1099, 1159, 1221,
1232, 1352, 1441, 1477, 1502, 1545, 1652, 3257, 3301 cm−1; 1H-NMR (DMSO-d6) 2.19 (3H, s, CH3), 6.88
(1H, s, 3-H), 7.04 (2H, d, J = 16.5 Hz, CH=CH), 7.18 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.23 (2H, d, J = 16.5 Hz,
CH=CH), 7.34 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.49 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, t, J = 8.7 Hz, 2”,6”-H),
7.84–7.89 (3H, m, 6-H and 2′,6′-H), 9.68 (1H, s, NH), 11.08 (1H, s, NH); 13C-NMR (DMSO-d6) 24.4,
100.2, 110.0, 112.7, 115.9 (d, 2JCF = 21.8 Hz), 116.4 (d, 2JCF = 20.6 Hz), 124.2, 124.7, 127.6 (d, 3JCF = 9.1
Hz), 128.3 (d, 3JCF = 8.0 Hz), 128.9 (d, 4JCF = 2.3 Hz), 129.5, 129.6, 130.3, 130.6, 134.6 (d, 4JCF = 2.3 Hz),
137.5, 161.7 (d, 1JCF = 241.6 Hz), 162.2 (d, 1JCF = 243.9 Hz), 169.0; HRMS (ES): MH+, found: 389.1465.
C24H19N2F2O+ requires: 389.1465.
(E)-N-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3g). A mixture of 2g (0.10 g, 0.25
mmol) and TFA (0.03 g, 0.25 mmol) in acetonitrile (5 mL) afforded 3g as a solid (0.07 g, 69%); Rf 0.33,
mp. 233–235 ◦C; νmax (ATR) 488, 516, 549, 584, 614, 746, 786, 809, 830, 843, 954, 1025, 1095, 1159, 1181,
1223, 1253, 1276, 1346, 1371, 1460, 1502, 1554, 1609, 1646, 3298 cm−1; 1H-NMR (DMSO-d6) 2.18 (3H,
s, CH3), 3.80 (3H, s, OCH3), 6.77 (1H, d, s, 3-H), 7.02 (1H, d, J = 15.9 Hz, CH=CH) 7.05 (2H, d, J = 8.1
Hz, 3′,5′-H), 7.17 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.22 (2H, d, J = 15.9 Hz, CH=CH), 7.45 (1H, d, J = 1.2 Hz,
4-H), 7.62 (2H, d, J = 8.7 Hz, 2”,6”-H), 7.75 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.82 (1H, d, J = 1.2 Hz, 6-H), 9.66
(1H, s, NH), 10.99 (1H, s, NH); 13C-NMR (DMSO-d6) 24.5, 55.7, 98.9, 112.1, 114.9, 115.4, 115.9 (d, 2JCF =
21.8 Hz), 124.1, 124.6, 124.9, 126.9, 128.3 (d, 3JCF = 8.0 Hz), 129.1, 129.3, 130.5 130.8, 134.6 (d, 4JCF = 3.4
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Hz), 138.6, 159.5, 161.7 (d, 1JCF = 242.8 Hz), 170.0; HRMS (ES): MH+, found: 401.1658. C25H22N2FO2+
requires: 401.1665.
3.4. Typical Procedure for the Trifluoroacetylation of 3a–g
A mixture of 3 (1 equivalent) and TFAA (1.5 equivalent) in THF (25 mL/mmol of 3) was heated at
60 ◦C for 5 h. The mixture was cooled to room temperature quenched with saturated sodium hydrogen
carbonate solution. The mixture was extracted with chloroform (3 × 20 mL) and the combined organic
layers were dried with anhydrous MgSO4 and the salt was filtered off. The solvent was evaporated
under reduced pressure and the residue was purified by column chromatography on a silica gel (60%
EtOAc–hexane as eluent) to afford 4 as a solid. Compounds 4a–g were prepared in this fashion.
N-(2,5-Bis(4-fluorophenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4a). A mixture of 3a (0.15 g,
0.41 mmol) and TFAA (0.13 g, 0.62 mmol) in THF (10 mL) afforded 4a as a solid (0.15 g, 79%), Rf 0.51,
mp. 215–218 ◦C; νmax (ATR) 436, 514, 565, 589, 644, 721, 744, 814, 832, 900, 927, 1013, 1041, 1098, 1143,
1186, 1202, 1225, 1374, 1436, 1513, 1605, 1634, 1653, 3251, 3312 cm−1; 1H-NMR (DMSO-d6) 2.13 (3H, s,
CH3), 7.30 (2H, t, J = 8.7 Hz, 3”,5”-H), 7.40 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.61–7.72 (4H, m, 2′,6′-H and
2”,6”-H), 7.91 (1H, d, J = 1.2 Hz, 4-H), 8.02 (1H, d, J = 1.2 Hz, 6-H), 9.83 (1H, s, NH), 12.47 (1H, s, NH);
13C-NMR (DMSO-d6) 24.2, 108 .1, 115.6 (d, 2JCF = 21.8 Hz), 116.2 (d, 2JCF = 21.8 Hz), 116.3, 116.7 (q,
1JCF = 288.6 Hz), 125.2, 127.9 (d, 4JCF = 3.5 Hz), 128.2, 128.7, 129.2 (d, 3JCF = 8.0 Hz), 132.8 (d, 3JCF
= 8.0 Hz), 135.6, 137.9 (d, 4JCF = 2.3 Hz), 148.2, 162.2 (d, 1JCF = 242.8 Hz), 163.6 (d, 1JCF = 246.2 Hz),
169.2, 170.8, 175.7 (q, 2JCF = 34.4 Hz); 19F-NMR (DMSO-d6) -115.9 (1F, ddd, J = 5.9, 8.7 and 14.7 Hz,
4′ ′-CF), −110.5 (1F, ddd, J = 4.8, 8.7 and 13.8 Hz, 4′-CF), −71.2 (3F, s, COCF3); HRMS (ES): MH+, found
459.1131. C24H16 N2F5O2+ requires: 459.1132.
N-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4b). A
mixture of 3b (0.15 g, 0.40 mmol) and TFAA (0.13 g, 0.60 mmol) in THF (10 mL) afforded 4b as
a solid (0.15 g, 86%), Rf 0.34, mp. 222–224 ◦C; νmax (ATR) 417, 517, 539, 569, 594, 713, 722, 834, 912,
963, 1014, 1038, 1144, 1180, 1206, 1249, 1291, 1435, 1473, 1513, 1612, 1634, 1654, 1676, 3209, 3276 cm−1;
1H-NMR (DMSO-d6) 2.13 (3H, s, CH3), 3.84 (3H, s, OCH3), 7.11 (2H, d, J = 8.4 Hz, 3′,5′-H), 7.30 (2H, t, J
= 8.7 Hz, 3”,5”-H), 7.57 (2H, d, J = 8.4 Hz, 2′,6′-H), 7.63 (2H, t, J = 8.7 Hz, 2”,6”-H), 7.91 (1H, d, J = 1.2
Hz, 4-H), 7.99 (1H, d, J = 1.2 Hz, 6-H), 9.80 (1H, s, NH), 12.33 (1H, s, NH); 13C-NMR (DMSO-d6) 24.2,
55.8, 107.7, 114.1 (2 × C), 115.0, 115.9, 116.2 (d, 2JCF = 20.6 Hz), 116.8 (q, 1JCF J = 288.5 Hz), 123.7, 125.1,
127.9, 129.0, 129.2 (d, 3JCF = 8.0 Hz), 131.8, 135.4, 138.0 (d, 4JCF = 3.4 Hz), 149.4, 161.1, 162.1 (d, 1JCF =
242.8 Hz), 169.2, 176.0 (q, 2JCF = 35.5 Hz); 19F-NMR (DMSO-d6) −116.0 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz,
4”-CF), −71.0 (3F, s, COCF3); HRMS (ES): MH+, found: 471.1333. C25H19N2F4O3+ requires: 471.1332.
N-(3-(2,2,2-Trifluoroacetyl)-2-(4-fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (4c). A mixture
of 3c (0.15 g, 0.40 mmol) and TFAA (0.13 g, 0.60 mmol) in THF (10 mL) afforded 4c as a solid (0.17 g,
89%), Rf 0.42, mp. 255–257 ◦C; νmax (ATR) 448, 504, 517, 545, 592, 624, 643, 729, 783, 808, 832, 850, 901,
929, 1019, 1123, 1157, 1180, 1219, 1244, 1302, 1369, 1448, 1515, 1566, 1604, 1632, 1657, 3185, 3245 cm−1;
1H-NMR (DMSO-d6) 2.11 (3H, s, CH3), 3.78 (3H, s, OCH3), 7.04 (2H, d, J = 7.5 Hz, 3”,5”-H), 7.39 (2H,
t, J = 7.5 Hz, 3′,5′-H), 7.55 (2H, d, J = 7.5 Hz, 2”,6”-H), 7.65–7.70 (2H, m, 2′,6′-H), 7.87 (1H, d, J = 1.2
Hz, 4-H), 7.99 (1H, d, J = 1.2 Hz, 6-H), 9.84 (1H, s, NH), 12.44 (1H, s, NH); 13C-NMR (DMSO-d6) 24.1,
55.6, 108.0, 114.5, 114.9, 115.6 (d, 2JCF = 21.8 Hz), 116.1, 116.8 (q, 1JCF = 288.5 Hz), 125.2, 127.9, 128.0 (d,
4JCF = 3.5 Hz), 128.3, 128.7, 132.8 (d, 3JCF = 9.1 Hz), 133.8, 136.4, 148.1, 159.2, 163.5 (d, 1JCF = 246.2 Hz),
169.3, 175.7 (q, 2JCF 35.5 Hz); 19F-NMR (282 MHz, DMSO-d6) −111.9 (1F, ddd, J 4.8, 8.7 and 14.7 Hz, 4′
-CF), −71.2 (3F, s, COCF3); HRMS (ES): MH+, found 471.1334. C25H19N2F4O3+ requires: 471.1332.
N-(2,5-Bis(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4d). A mixture of 3d (0.15 g,
0.39 mmol) and TFAA (0.12 g, 0.58 mmol) in THF (10 mL) afforded 4b as a solid (0.17 g, 90%), Rf 0.28,
mp. 254–257 ◦C; νmax (ATR) 528, 545, 594, 643, 714, 729, 798, 852, 900, 928, 966, 1026, 1137, 1178, 1201,
1235, 1253, 1295, 1436, 1450, 1516, 1566, 1607, 1655, 1673, 3171, 3251 cm−1; 1H-NMR (DMSO-d6) 2.13
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(3H, s, CH3), 3.79 (3H, s, OCH3), 3.85 (3H, s, OCH3), 7.05 (2H, d, J = 8.7 Hz, 3”,5”-H), 7.12 (2H, d, J =
8.7 Hz, 3′,5′-H), 7.54 (2H, d, J = 8.4 Hz, 2”,6”-H), 7.57 (2H, d, J = 8.4 Hz, 2′,6′-H), 7.88 (1H, d, J = 1.2 Hz,
4-H), 7.98 (1H, d, J = 1.2 Hz, 6-H), 9.78 (1H, s, NH), 12.28 (1H, s, NH); 13C-NMR (DMSO-d6) 24.2, 55.6,
55.8, 107.6, 114.1, 114.5, 114.9, 115.8, 116.8 (q, 1JCF = 288.6 Hz), 123.7, 125.0, 127.7, 128.1, 128.3, 129.0,
131.8, 133.9, 136.2, 149.2, 159.2, 161.1, 169.2, 175.9 (q, 2JCF = 34.4 Hz); 19F-NMR (DMSO-d6) −71.0 (3F, s,
COCF3); HRMS (ES): MH+, found: 483.1533. C26H22N2F3O4+ requires: 483.1532.
(E)-N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-phenyl-1H-indol-7-yl] Acetamide (4e). A mixture of
3e (0.15 g, 0.41 mmol) and TFAA (0.13g, 0.61 mmol) in THF (10 mL) afforded 4e as a solid (0.15 g, 80%),
Rf 0.35, mp. 230–233 ◦C; νmax (ATR) 475, 507, 527, 599, 674, 702, 731, 750, 773, 818, 852, 915, 962, 1012,
1141, 1184, 1224, 1260, 1285, 1370, 1434, 1456, 1508, 1558, 1628, 1657, 1667, 3198, 3331 cm−1; 1H-NMR
(DMSO-d6) 2.12 (3H, s, CH3), 7.13 (1H, d, J = 16.5 Hz, CH=CH), 7.19 (2H, t, J = 8.1 Hz, 3”,5”-H), 7.37
(1H, d, J = 16.5 Hz, CH=CH), 7.57–8.00 (5H, m, 4′-H, 3′,5′-H, and 2”,6”-H), 7.68–7.72 (2H, m, 2′,6′-H),
7.92 (1H, d, J = 1.2 Hz, 4-H), 8.02 (1H, d, J = 1.2 Hz, 6-H) 9.74 (1H, s, NH), 12.43 (1H, s, NH); 13C-NMR
(DMSO-d6) 24.1, 107.1, 115.4, 116.0 (d, 2JCF = 21.8 Hz), 116.2, 116.7 (q, 1JCF = 288.5 Hz), 124.8, 125.0,
126.6, 128.6, 128.8 (d, 3JCF = 8.0 Hz), 129.6, 129.7, 130.3, 130.4, 131.6, 133.3, 134.2 (d, 4JCF = 2.3 Hz), 149.0,
162.0 (d, 1JCF = 242.8 Hz), 169.2, 176.0 (q, 2JCF = 35.5 Hz); 19F-NMR (DMSO-d6) −114.6 (1F, ddd, J = 5.9,
8.7 and 14.7 Hz, 4”-CF), −71.02 (3F, s, COCF3); HRMS (ES): MH+, found: 467.1384. C26H19N2F4O2+
requires: 467.1383.
N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-(4-fluorophenyl)-1H-indol-7-yl] Acetamide (4f). A mixture
of 3f (0.15 g, 0.39 mmol) and TFAA (0.12 g, 0.58 mmol) in THF (10 mL) afforded 4f as a solid (0.15 g,
81%), Rf 0.34, mp. 222–225 ◦C; νmax (ATR) 478, 514, 524, 578, 624, 733, 785, 816, 845, 920, 964, 1012, 1097,
1156, 1197, 1226, 1301, 1372, 1446, 1507, 1598, 1641, 1657, 3181, 3251 cm−1; 1H-NMR (DMSO-d6) 2.12
(3H, s, CH3), 7.14 (1H, d, J = 16.5 Hz, CH=CH), 7.20 (2H, t, J = 9.3 Hz, 3”,5”-H), 7.37 (1H, d, J = 16.5 Hz,
CH=CH), 7.41 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.66–7.73, (4H, m, 2′,6′-H and 2”,6”-H), 7.88 (1H, d, J = 1.2 Hz,
4-H), 8.01 (1H, d, J = 1.2 Hz, 6-H), 9.77 (1H, s, NH), 12.43 (1H, s, NH); 13C-NMR (DMSO-d6) 24.1, 107.1,
114.8, 115.6 (d, 2JCF = 21.8 Hz), 116.0 (d, 2JCF = 20.6 Hz), 116.2, 116.3, 117.0 (q, 1JCF = 230.2 Hz), 125.0,
126.6, 128.0 (d, 4JCF 3.5 Hz), 128.6, 128.8 (d, 3JCF 8.0 Hz), 129.0, 129.6, 132.8 (d, 3J J 8.0 Hz), 133.3, 134.2
(d, 4JCF = 3.5 Hz), 147.9, 162.0 (d, 1JCF = 243.9 Hz), 163.5 (d, 1JCF = 246.2 Hz), 175.8 (q, 2JCF = 34.4 Hz);
19F-NMR (DMSO-d6) −114.6 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz 4”-CF), −110.9 (1F, ddd, J = 5.9, 9.0 and
14.9 Hz, 4′-CF), −71.2 (3F, s, COCF3); HRMS (ES): MH+, found: 485.1285. C26H18N2F5O2+ requires:
485.1288.
((E)-N-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4g).
A mixture of 3g (0.15 g, 0.38 mmol) and TFAA (0.12 g, 0.56 mmol) in THF (10 mL) afforded 4g as a
solid (0.14 g, 74%), Rf 0.20, mp. 264–267 ◦C; νmax (ATR) 466, 527, 613, 633, 730, 749, 749, 817, 817, 846,
893, 922, 964, 1007, 1030, 1046, 1118, 1133, 1177, 1200, 1212, 1229, 1251, 1292, 1369, 1391, 1442, 1506,
1560, 1606, 1653, 1668, 3179, 3240 cm−1; 1H-NMR (DMSO-d6) 2.12 (3H, s, CH3), 3.84 (3H, s, OCH3), 7.11
(2H, d, J = 8.7 Hz, 3′,5′-H), 7.14-7.22 (3H, m, CH=CH and 3”,5”-H), 7.36 (1H, d, J = 16.5 Hz, CH=CH),
7.55 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.70 (2H, d, J = 8.7 Hz, 2”,6”-H), 7.89 (1H, d, J = 1.2 Hz, 4-H), 7.99 (1H,
d, J = 1.2 Hz, 6-H) 9.74 (1H, s, NH), 12.30 (1H, s, NH); 13C-NMR (DMSO-d6) 24.2, 55.8, 107.7, 114.1 (2 ×
C), 115.2, 116.0 (d, 2JCF = 20.6 Hz), 116.7 (q, 1JCF J = 289.7 Hz), 123.7, 124.9, 126.5, 128.7, 128.8 (d, 3JCF =
8.0 Hz), 129.6, 129.7, 131.8, 133.1, 134.2 (d, 4JCF = 2.3 Hz), 149.1, 161.1, 162.0 (d, 1JCF = 242.8 Hz), 169.2,
176.1 (q, 2JCF = 35.6 Hz); 19F-NMR (DMSO-d6) -114.6 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz, 4”-CF), -71.0 (3F,
s, COCF3); HRMS (ES): MH+, found: 497.1488. C27H21F4N2O3+ requires: 497.1488.
3.5. Typical Procedure for the One-pot Sequential Beckmann Rearrangement of 2a–g and Subsequent
Trifluoroacetylation
A mixture of 2 (1 equivalent) and TFA (1.2 equivalent) in acetonitrile (25 mL/mmol of 2) was
refluxed at 80 ◦C for 2 h. TFAA (2 equiv.) was added to the mixture and heating was continued for
5 h at this temperature. The solvent was evaporated under reduced pressure and the residue was
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quenched with an ice-cold water. The product was extracted with chloroform and the combined
organic layers were dried over anhydrous MgSO4. The salt was filtered off and then the solvent was
evaporated under reduced pressure on a rotary evaporator. The residue was purified by column
chromatography on a silica gel to afford 4 as a solid. Products 4a–f were prepared in this fashion.
N-(2,5-Bis(4-fluorophenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4a). A mixture of 2a (0.15 g,
0.41 mmol) and TFA (0.06 g, 0.50 mmol) in CH3CN (10 mL) followed by treatment with TFAA (0.17 g,
0.83 mmol) afforded 4a as a solid (0.14 g, 74%).
N-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4b). A mixture
of 2b (0.15 g, 0.40 mmol) and TFA (0.05 g, 0.48 mmol) in CH3CN (10 mL) followed by treatment with
TFAA (0.17 g, 0.80 mmol) afforded 4b as a solid (0.15 g, 80%).
N-(3-(2,2,2-Trifluoroacetyl)-2-(4-fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (4c). A mixture
of 2c (0.15 g, 0.40 mmol) and TFA (0.05 g, 0.48 mmol) in CH3CN (10 mL) followed by treatment with
TFAA (0.17 g, 0.80 mmol) afforded 4c as a solid (0.16 g, 82%).
N-(3-(2,2,2-Trifluoroacetyl)-2,5-bis(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (4d). A mixture of 2d (0.15 g,
0.39 mmol) and TFA (0.05 g, 0.47 mmol) in CH3CN (10 mL) followed by treatment with TFAA (0.16 g,
0.78 mmol) afforded 4d as a solid (0.16 g, 84%).
(E)-N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-phenyl-1H-indol-7-yl] Acetamide (4e). A mixture of
2e (0.15 g, 0.41 mmol) and TFA (0.6 g, 0.48 mmol) in CH3CN (10 mL) followed by treatment with TFAA
(0.17 g, 0.81 mmol) afforded 4e as a solid (0.14 g, 76%).
(E)-N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-(4-fluorophenyl)-1H-indol-7-yl] Acetamide (4f). A mixture
of 2f (0.15 g, 0.39 mmol) and TFA (0.05 g, 0.46 mmol) in CH3CN (10 mL) followed by treatment with
TFAA (0.16 g, 0.77 mmol) afforded 4f as a solid (0.15 g, 79%).
((E)-N-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4g). A mixture
of 2g (0.15 g, 0.38 mmol) and TFA (0.05 g, 0.46 mmol) in CH3CN (10 mL) followed by treatment with
TFAA (0.16 g, 0.75 mmol) afforded 4g as a solid (0.13 g, 72%).
3.6. pLDH Asssay
Three-fold serial dilutions of the test compounds were incubated in triplicates with 3D7 strain
P. falciparum parasites in a transparent 96-well flat bottom plate. DMSO and chloroquine were used as
negative and positive controls, respectively. The plate was put in an airtight box, gassed and incubated
with complete RPMI 1640 medium for 48 h. At the end of incubation, Malstat reagent was added to the
96-well plate followed by developing with NBT/PES (nitro blue tetrazolium + phenazine ethosulphate)
reagent. Parasite growth was determined spectrophotometrically at 620 nm, by measuring the activity
of the pLDH in control and drug-treated cultures using an Infinite F500 multiwell plate reader (Tecan
Group Ltd., Zürich, Switzerland). The OD values from control wells devoid of drug were referred to
as having 100% pLDH activity. The IC50 are expressed as the % parasite survival relative to the control,
calculated from fitted sigmoidal dose response curves. The dose response curves were obtained by
plotting percentage parasite survival against the logarithm of the concentration using the GraphPad
Prism software package (GraphPad software Inc., La Jolla, CA, USA). IC50 values were calculated
graphically by interpolation from these curves.
3.7. In Vitro Cytotoxicity Assay
Monkey kidney cells (Vero) used in this experiment were obtained from Cellonex (Johannesburg,
South Africa). The cells were maintained in Dulbecco’s Modified Eagle’s (DMEM, HyClone, Thermo
Scientific, Aalst, Belgium) supplemented with 0.4 mML-glutamine and sodium pyruvate and 10%
foetal bovine serum (FBS, HyClone, Thermo Scientific). The cells of a sub-confluent culture were
harvested using trypsin-EDTA (HyClone, Thermo Scientific) and centrifuged at 200× g for 5 min
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and re-suspended in growth medium to 5 × 104 cells/mL. A total of 200 µL of the cell suspension
was pipetted into each well of columns 2 to 11 of a 96 well culture plate. The same amount of the
growth medium was added to wells of column 1 and 12 to maintain humidity and minimize the
edge effect. The plates were incubated at 37 ◦C in a 5% CO2 incubator overnight until the cells were
in the exponential phase of growth. After incubation, the DMEM was aspirated from the cells and
replaced with 200 µL of different concentrations of the test samples (0.1–100 µM). Each dilution of
the test sample was tested in quadruplicate in each experiment and the experiments were repeated
three times. The plates were again incubated for 2 days at 37 ◦C in a 5% incubator. A negative
control (untreated cells) and positive control (cells treated with different concentrations of doxorubicin
hydrochloride, Sigma, Schnelldorf, Germany) were included. After incubation, 30 µL of 5 mg/mL MTT,
(Sigma-Aldrich, GmBH, Schnelldorf, Germany) in phosphate buffered saline PBS was added to each
well and the plates were incubated for a further 4 h at 37 ◦C. After incubation with MTT, the medium
in each well was removed and the formazan crystals formed were dissolved by adding 50 µL of DMSO
to each well of the plates. The plates were gently shaken until the crystals were dissolved. The amount
of MTT reduction was measured immediately by detecting the absorbance using a microplate reader
at a wavelength of 570 nm (BioTek Synergy, Analytical and Diagnostic Products, Johannesburg, South
Africa). The wells in column 1 and 12, containing medium and MTT but no cells was used to blank the
microplate reader. The percentage of cell viability was calculated using the formula below:
%Cell viability =
Mean Absorbance of sample × 100
Mean Absorbance of control
The LC50 values (lethal concentration at which 50% of the cells are killed) were calculated as the
concentration of the test sample that resulted in 50% reduction of absorbance compared to untreated
cells. The intensity of the MTT formazan produced by living metabolically active cells is directly
proportional to the number of live cells present.
3.8. Methodology-Docking Simulation
3.8.1. Protein Structure
The starting structure of parasite lactate dehydrogenase (pLDH) was obtained from PDB (PDB id:
1T24) with 1.7 Å resolution. All heteroatoms and water molecules were removed pLDH. Polar hydrogen
atoms, Kollman-Amber united atom partial charges and solvation parameters were added by utilizing
AutoDockTools [29].
3.8.2. Ligand Structure
The initial structure of positive control 4-hydroxy-1,2,5-oxazole-3-carboxylic acid (OXD) was
obtained from the ligand of pLDH (PDB id: 1T24) while the coordinates for test compound 3a, 3f, 4a
and 4g were generated using Hyperchem 7.0 (Hypercube Inc., Gainesville, FL, USA). All ligands were
retained with polar hydrogen atoms. Gasteiger charges and torsional angles were added by utilizing
AutoDockTools [29].
3.8.3. Molecular Docking Simulation
Grid maps of 40 × 40 × 40 points with 0.375 Å spacing were centered at OXD binding site in the
crystal structure (PDB id: 1T24) for positive control docking and the docking of lactate (the substrate
of pLDH). While for compound 3(a,f) and 4(a,g), the grid maps of 50 × 50 × 50 points with 0.375 Å
spacing were centered at NAD+ of the crystal structure (PDB id: 1T24). A total of 200 docking runs
by AutoDock4.2.6 [30] were performed by employing Lamarckian genetic algorithm with 2,500,000
energy evaluations per run and maximum number of 27,000 generation. The number of individuals
in population was 150 and the crossover rate was 0.8. The results were processed by conformational
cluster analysis with 1.0 Å cut-off for positive control and 2.0 Å cut-off for lactate, 3(a,f) and 4(a,g).
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The ligand conformation with lowest free energy of binding in the most populated cluster was selected
for comparison.
4. Conclusions
The oximes derived from the 1-(2,5-diarylindol-7-yl)ethanones undergo sequential or direct
one-pot successive TFA-mediated Beckmann rearrangement followed by trifluoroacetylation of the
intermediate N-(2,5-diarylindol-7-yl)acetamides with TFAA to afford the C-3 trifluoroacetylated
derivatives, exclusively. The preliminary in vitro antiplasmodial activity results against the
chloroquine-sensitive strain of malaria parasite for both N-(2,5-diarylindol-7-yl)acetamides and their
3-trifluoroacetyl–substituted derivatives reveal that the entire 7-aminoindole framework is required for
biological activity. Structure-activity relationship and molecular docking indicate that the optimal aryl
substituent at the 5-position of the indole derivatives 3 and 4 is the 4-fluorophenyl or 4-fluorostyryl
group. Molecular docking of the most active compounds 3a, 3f, 4a and 4g against the parasite lactate
dehydrogenase (pLDH) reveal that the indole derivatives prepared in this investigation presumably
act through different mechanism of action to that of chloroquine. They will probably not compete with
lactate for its binding site, but might block the entrance of lactate to cause the observed inhibition effects.
Future studies should involve an enzyme inhibition assay against lactate dehydrogenase activity to
measure parasite viability. Despite the fact that the IC50 values of these compounds (1400–14,000 nM)
fall much short of the nanomolar activity of chloroquine (10 nM), these preliminary antiplasmodial
activity results suggest that the indole derivatives are worthy of further studies to develop new drugs
with novel mechanisms of action and reduced toxicity.
Supplementary Materials: The following materials are available online. The % cell viability and IC50 values as
well graphs for compounds 3a–g and 4a–g as well as X-ray data.
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